This material is an English translation of the press release announced on Mar. 30, 2023 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Notice regarding Revision of Earnings Forecast

We would like to announce that we have revised the full-year earnings forecast for the fiscal year ending February 28, 2023, from the consolidated earnings forecast announced on April 7, 2022, as follows.

1. Revision of consolidated earnings forecast

Revision of consolidated earnings forecast figures for the fiscal year ending February 28, 2023 (March 1, 2022 to February 28, 2023)

(Million yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Current net income per share
Previous forecast (A)	123,000	11,100	12,700	9,700	119.44 yen
Revised forecast (B)	128,300	11,500	16,000	12,000	151.25 yen
Amount of change (B-A)	+5,300	+400	+3,300	+2,300	
Ratio of change (%)	+4.3%	+3.6%	+26.0%	+23.7%	
Results of the previous fiscal year (Fiscal year ended February 28, 2022)	120,193	9,337	12,638	9,658	118.92 yen

2. Reason for revision

Sales in the domestic market fell from the forecasted level. However, because sales in the overseas market grew for OTC pharmaceuticals, focusing on Salonpas®, and the impact of the weaker yen, among other factors, our consolidated performance for the FY ended February 2023 is forecasted to surpass the previously-announced figures, both in sales and operating profit.
Ordinary and net profits are also expected to surpass the previously-announced forecasts. This is because, in addition to operating profit surpassing the predicted level, foreign exchange gains are anticipated to increase from the initial expectations in the extraordinary income and expenses.

* The above forecasted figures for earnings are based on the information available as of the announcement date, and actual results may differ from the forecasted figures due to various factors in the future.